Subject: Re: ALZ
if one is aware of the critical nature payload packaging&delivery had to do with mRNA breakthroughs, try googling 'roche brain shuttle'.
it could be a critical piece in any future ALZ intervention.

this may be some further pattern forcing, but consider that despite being heavily analyzed & tracked mega caps, the GLP1 business success of novo and lilly came as a surprise to experts well aware of diabetes research.
in the same way, i see 'latent' research gems at roche in the field of neurology, further substantiated by their biogen partnership.

if not ALZ, roche is still one of the best run global revenue companies that is inexpensive by being out of the S&P500.